Skip to main content
. 2013 Nov 7;2013:685150. doi: 10.1155/2013/685150

Figure 3.

Figure 3

Growth curves showed the proliferation of MHCC97H cells until 72 h by CCK-8 assay. NET-1shRNA, sorafenib, and combination of NET-1shRNA with sorafenib resulted in 14.6%, 19.3%, and 33.3% reduction of cell proliferation at 48 h, in 46.5%, 50.6%, and 66.3% reduction of cell proliferation at 72 h. ( P < 0.05 compared with untreated group. *P < 0.05 compared with combination group).